Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Phase 2b, Multicenter Study to Evaluate the Safety, Efficacy, and Tolerability of SNA-120 (Pegcantratinib) Ointment in Subjects With Pruritus Associated With Psoriasis Vulgaris

NCT03322137 is registered in ClinicalTrials.gov with Sienna Biopharmaceuticals as lead sponsor.

NCT NCT03322137
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03322137 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Phase 2b, Multicenter Study to Evaluate the Safety, Efficacy, and Tolerability of SNA-120 (Pegcantratinib) Ointment in Subjects With Pruritus Associated With Psoriasis Vulgaris
Lead sponsor
Sienna Biopharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
October 10, 2017
Completion date
October 22, 2018
Enrollment
208 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

pruritus, psoriasis vulgaris